TeselaGen Biotechnology

Executive Summary

TeselaGen Biotechnology is a San Francisco-based private company that has developed Tesela AI, an AI-powered software platform designed to accelerate the Design-Build-Test-Learn (DBTL) cycle in biological research and development. By leveraging specialized AI agents, Tesela AI integrates with existing lab infrastructure such as ELNs and LIMS to automate tasks like DNA library design, sequence optimization, and protocol generation. This aims to reduce the time and cost of biotech R&D, making it a valuable tool for synthetic biology, drug discovery, and industrial biotechnology. The company was founded in 2011 and operates in the competitive AI-driven biotech space, with a focus on enhancing productivity for scientists. While financial details are undisclosed, TeselaGen's platform addresses a critical bottleneck in biotech, positioning it for potential adoption by large pharma and biotech firms. The company's growth trajectory will depend on its ability to secure partnerships and funding to scale its go-to-market efforts.

Upcoming Catalysts (preview)

• Q3 2026Partnership with major pharmaceutical company to deploy Tesela AI across internal R&D teams70% success
• Q3 2026Series A funding raise to accelerate product development and sales75% success
• Q4 2026Launch of Tesela AI v2.0 with new features for automated protocol generation80% success